Pediatric Grand Rounds (RECORDING) Pediatric COVID-19 and COVID-19 Vaccine Update

This presentation is a recording of a Stanford Pediatric Grand Rounds Session.  World-renowned experts will present the latest research, practice guidelines, and treatment protocols to advance best practices in the care of pediatric patients. These online recordings will provide pediatricians and family physicians with up-to-date clinical information on a wide range of clinical issues encountered in daily pediatric practice. In this session, we review what the current status of COVID-19 epidemiology with a focus on pediatrics, including what we currently understand about the omicron variants, the current efficacy and effectiveness of the COVID-19 vaccines including boosters, and where we still have knowledge gaps.

  Release Date: June 30, 2023
  Expiration Date: June 29, 2024
  Estimated Time to Complete: 1.0 hour
  Registration Fee: FREE
 *Originally recorded 04/13/2023.

1. Define the current epidemiology of SARS-CoV-2 infection and COVID-19 disease in children.
2. Determine the clinical and epidemiologic manifestations of the omicron variants, including what is known about long COVID in children.
3. Define the efficacy and effectiveness of COVID-19 vaccines and boosters across general and pediatric populations.
4. Identify the risk benefit of COVID-19 vaccines in a variety of populations, including children.

In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Credit Designation 
American Medical Association (AMA) 
Stanford Medicine designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credits^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accessibility Statement
 Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require accommodations, please contact the CME Conference Coordinator.

Cultural and Linguistic Competency
The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area for the purpose of complying with California Assembly Bill 1195. Moreover, the Stanford University School of Medicine Multicultural Health Portal contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws.  You are encouraged to visit the Multicultural Health Portal: https://laneguides.stanford.edu/multicultural-health

References/Bibliography

Alsoussi, W. B., Malladi, S. K., Zhou, J. Q., Liu, Z., Ying, B., Kim, W., Schmitz, A. J., Lei, T., Horvath, S. C., Sturtz, A. J., McIntire, K. M., Evavold, B., Han, F., Scheaffer, S. M., Fox, I. F., Parra-Rodriguez, L., Nachbagauer, R., Nestorova, B., Chalkias, S., Farnsworth, C. W., … Ellebedy, A. H. (2022). SARS-CoV-2 Omicron boosting induces de novo B cell response in humans. bioRxiv : the preprint server for biology, 2022.09.22.509040. https://doi.org/10.1101/2022.09.22.509040

Altarawneh, H. N., Chemaitelly, H., Ayoub, H. H., Hasan, M. R., Coyle, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G. K., Al-Kuwari, M. G., Butt, A. A., Al-Romaihi, H. E., Al-Thani, M. H., … Abu-Raddad, L. J. (2022). Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants. The New England journal of medicine, 387(17), 1620–1622. https://doi.org/10.1056/NEJMc2209306

American Academy of Pediatrics, the. (2023). AAP Schedule of Well-Child Care Visits. The American Academy of Pediatrics, healthychildren.org. https://www.healthychildren.org/English/family-life/health-management/Pages/Well-Child-Care-A-Check-Up-for-Success.aspx

American Academy of Pediatrics, the., & Children’s Hospital Association, the. (2023). Children and COVID-19: State Data Report, 4/6/2023. The American Academy of Pediatrics, AAP. https://downloads.aap.org/AAP/PDF/AAP%20COVID-19%20State%20Data%20Report%204.6.23%20FINAL.pdf

Cao, Y., Jian, F., Wang, J., Yu, Y., Song, W., Yisimayi, A., Wang, J., An, R., Chen, X., Zhang, N., Wang, Y., Wang, P., Zhao, L., Sun, H., Yu, L., Yang, S., Niu, X., Xiao, T., Gu, Q., Shao, F., … Xie, X. S. (2023). Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature, 614(7948), 521–529. https://doi.org/10.1038/s41586-022-05644-7

Centers for Disease Control and Prevention. (2022). CDC Expands Updated COVID-19 Vaccines to Include Children Ages 6 Months through 5 Years. Centers for Disease Control and Prevention. https://www.cdc.gov/media/releases/2022/s1209-covid-vaccine.html

Centers for Disease Control and Prevention. (2023). COVID Data Tracker Weekly Review. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/past-reports/01062023.html

Centers for Disease Control and Prevention. (2023). Nationwide Commercial Lab Pediatric Antibody Seroprevalence. Centers for Disease Control and Prevention, COVID Data Tracker. https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence 

Centers for Disease Control and Prevention. (2023). Provisonal COVID-19 Deaths Counts by Age. Centers for Disease Control and Prevention. https://data.cdc.gov/NCHS/Provisional-COVID-19-Death-Counts-by-Age-in-Years-/3apk-4u4f/data

Centers for Disease Control and Prevention. (2023). Rates of COVID-19 Associated Hospitalizations. Centers for Disease Control and Prevention, The Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). https://gis.cdc.gov/grasp/covidnet/COVID19_3.html

Collier, A. Y., Miller, J., Hachmann, N. P., McMahan, K., Liu, J., Apraku Bondzie, E., Gallup, L., Rowe, M., Schonberg, E., Thai, S., Barrett, J., Borducchi, E. N., Bouffard, E., Jacob-Dolan, C., Mazurek, C. R., Mutoni, A., Powers, O., Sciacca, M., Surve, N., VanWyk, H., … Barouch, D. H. (2022). Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters. bioRxiv : the preprint server for biology, 2022.10.24.513619. https://doi.org/10.1101/2022.10.24.513619

Davis-Gardner, M. E., Lai, L., Wali, B., Samaha, H., Solis, D., Lee, M., Porter-Morrison, A., Hentenaar, I. T., Yamamoto, F., Godbole, S., Douek, D. C., Lee, F. E., Rouphael, N., Moreno, A., Pinsky, B. A., & Suthar, M. S. (2022). mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1. bioRxiv : the preprint server for biology, 2022.10.31.514636. https://doi.org/10.1101/2022.10.31.514636

Food and Drug Administration. (2023). Coronavirus (COVID-19) Update: FDA Authrorizes Bivalent Pfizer-BioNTech COVID-19 Vaccine as Booster Dose for Certain Children 6 Months through 4 Years of Age. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-bivalent-pfizer-biontech-covid-19-vaccine-booster-dose

Food and Drug Administration. (2022). Coronavirus (COVID-19) Update: FDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-updated-bivalent-covid-19-vaccines-children-down-6-months

Goddard, K., Hanson, K. E., Lewis, N., Weintraub, E., Fireman, B., & Klein, N. P. (2022). Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States. Annals of internal medicine, 175(12), 1169–1771. https://doi.org/10.7326/M22-2274

Kurhade, C., Zou, J., Xia, H., Liu, M., Chang, H. C., Ren, P., Xie, X., & Shi, P. Y. (2023). Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nature medicine, 29(2), 344–347. https://doi.org/10.1038/s41591-022-02162-x

Lee, I. T., et al. (2023). A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273. medRxiv. https://doi.org/10.1101/2023.01.24.23284869 

Lozito, A., Das, R., Edwards, D., Moderna, Inc. (2023). Moderna COVID-19 Bivalent Vaccines Primary Series and Booster. Food and Drug Administration. https://www.fda.gov/media/164810/download

Laidlaw, B. J., & Ellebedy, A. H. (2022). The germinal centre B cell response to SARS-CoV-2. Nature reviews. Immunology, 22(1), 7–18. https://doi.org/10.1038/s41577-021-00657-1

Medical Dictionary for Regulatory Activities. (2023). MedDRA Hierarchy, Basics: How to Use. MedDRA. https://www.meddra.org/how-to-use/basics/hierarchy

Miller, J., Hachmann, N. P., Collier, A. Y., Lasrado, N., Mazurek, C. R., Patio, R. C., Powers, O., Surve, N., Theiler, J., Korber, B., & Barouch, D. H. (2023). Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1. The New England journal of medicine, 388(7), 662–664. https://doi.org/10.1056/NEJMc2214314

Muecksch, F., Weisblum, Y., Barnes, C. O., Schmidt, F., Schaefer-Babajew, D., Wang, Z., C Lorenzi, J. C., Flyak, A. I., DeLaitsch, A. T., Huey-Tubman, K. E., Hou, S., Schiffer, C. A., Gaebler, C., Da Silva, J., Poston, D., Finkin, S., Cho, A., Cipolla, M., Oliveira, T. Y., Millard, K. G., … Bieniasz, P. D. (2021). Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity, 54(8), 1853–1868.e7. https://doi.org/10.1016/j.immuni.2021.07.008

Muñoz, F. M., Sher, L. D., Sabharwal, C., Gurtman, A., Xu, X., Kitchin, N., Lockhart, S., Riesenberg, R., Sexter, J. M., Czajka, H., Paulsen, G. C., Maldonado, Y., Walter, E. B., Talaat, K. R., Englund, J. A., Sarwar, U. N., Hansen, C., Iwamoto, M., Webber, C., Cunliffe, L., … C4591007 Clinical Trial Group (2023). Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age. The New England journal of medicine, 388(7), 621–634. https://doi.org/10.1056/NEJMoa2211031

Rao, S., Lee, G. M., Razzaghi, H., Lorman, V., Mejias, A., Pajor, N. M., Thacker, D., Webb, R., Dickinson, K., Bailey, L. C., Jhaveri, R., Christakis, D. A., Bennett, T. D., Chen, Y., & Forrest, C. B. (2022). Clinical Features and Burden of Postacute Sequelae of SARS-CoV-2 Infection in Children and Adolescents. JAMA pediatrics, 176(10), 1000–1009. https://doi.org/10.1001/jamapediatrics.2022.2800

Reynolds, C. J., Pade, C., Gibbons, J. M., Otter, A. D., Lin, K. M., Muñoz Sandoval, D., Pieper, F. P., Butler, D. K., Liu, S., Joy, G., Forooghi, N., Treibel, T. A., Manisty, C., Moon, J. C., COVIDsortium Investigators§, COVIDsortium Immune Correlates Network§, Semper, A., Brooks, T., McKnight, Á., Altmann, D. M., … Moon, J. C. (2022). Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science (New York, N.Y.), 377(6603), eabq1841. https://doi.org/10.1126/science.abq1841

Schiepers, A., van 't Wout, M. F. L., Greaney, A. J., Zang, T., Muramatsu, H., Lin, P. J. C., Tam, Y. K., Mesin, L., Starr, T. N., Bieniasz, P. D., Pardi, N., Bloom, J. D., & Victora, G. D. (2023). Molecular fate-mapping of serum antibody responses to repeat immunization. Nature, 615(7952), 482–489. https://doi.org/10.1038/s41586-023-05715-3

Wang, Q., Bowen, A., Valdez, R., Gherasim, C., Gordon, A., Liu, L., & Ho, D. D. (2023). Antibody Response to Omicron BA.4-BA.5 Bivalent Booster. The New England journal of medicine, 388(6), 567–569. https://doi.org/10.1056/NEJMc2213907

For CME general questions, please contact 
     Email: [email protected]

Mitigation of Relevant Financial Relationships

Stanford Medicine adheres to the Standards for Integrity and Independence in Accredited Continuing Education. 

There are no relevant financial relationships with ACCME-defined ineligible companies for anyone who was in control of the content of this activity, except those listed in the table below. All of the relevant financial relationships listed for these individuals have been mitigated.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Alan R. Schroeder, MD
Clinical Professor
Stanford University

Co-Course Director

Olivera Marsenic Couloures, MD
LPCH

Course Director and Reviewer

Nothing to disclose

Yvonne Maldonado
Senior Associate Dean, Faculty Development and Diversity, Taube Professor of Global Health and Infectious Diseases, Professor of Pediatrics (Infectious Diseases) and of Epidemiology and Population Health
Stanford University School of Medicine

Faculty

Grant or research support-Pfizer, Inc.|Independent Contractor (included contracted research)-Pfizer, Inc.|Honoraria-National Institutes of Health|Grant or research support-Pfizer, Inc.

Debra Babcock, MD
Stanford Childrens (PCHA)

Planner

Nothing to disclose

Lisa Jo Chamberlain, MD
Professor of Pediatrics – General Pediatrics
Stanford Children's Health

Planner

Baraka Dechelle Floyd, MD
Clinical Assistant Professor and Associate Chair for Diversity, Equity, and Inclusion
Stanford University School of Medicine

Planner

Nothing to disclose

Charles Gawad, MD, PhD
Associate Professor
Stanford

Planner

Allison Guerin, EdD
Stanford

Planner

Nothing to disclose

Mary Beth Leonard, MSCE, MD, MSCE
Arline and Pete Harman Professor and Chair, Department of Pediatrics
Stanford University

Planner

Nothing to disclose

Ryan Lion, MD, MS
Stanford University

Planner

Nothing to disclose

Lauren E. E O'Brien, MD
Clinical Assistant Professor
LPCH

Planner

Nothing to disclose

Stephen J Roth, MPH, MD
Attending, Cardiovascular ICU
Lucile Packard Children's Hospital Stanford

Planner

Nothing to disclose

Stephanie Squires, MD
Pediatric Hospital Medicine Fellow
Stanford Health Care/ Stanford Children's Hospital

Planner

Nothing to disclose

Ke-You Zhang, MD
Stanford University

Planner

Nothing to disclose